Loading...

ImmunoGen, Inc.

IMGN•NASDAQ
Healthcare
Biotechnology
$31.23
$0.005(0.02%)

ImmunoGen, Inc. (IMGN) Stock Overview

Explore ImmunoGen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.4/100

Key Financials

Market Cap8.7B
P/E Ratio-35.54
EPS (TTM)$-0.28
ROE-1.43%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$70.78

IMGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmunoGen, Inc. (IMGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $70.78.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -35.54 and a market capitalization of 8.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for IMGNStats details for IMGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for IMGNAnalyst Recommendations details for IMGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO

Mark Joseph Enyedy

Employees

277

Headquarters

830 Winter Street, Waltham, MA

Founded

1989

Frequently Asked Questions

;